Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors a mechanism distinct from approved agents such as semaglutide or tirzepatide
More research is needed, but taking hormone therapy along with a GLP-1 may have profound effects for women in the menopause transition
Suppose you have a 5 mg vial and want a 500 mcg (0.5 mg) dose to read as exactly 25 units (0.25 mL)
By day 30, it is essentially gone
Classical nephroprotective treatment SLE patients have a higher mortality rate than the general population, with infections, cardiovascular (CV) complications, and especially renal failure as the leading causes of death (10) SLE patients present both traditional (dyslipidemia, smoking, obesity) and non-traditional (proteinuria, inflammation) CV risk factors
Methyl cycle dysfunction explains why one individual is damaged by environmental toxins, while others living in the same environment are unaffected